L. Bouhlel

771 total citations · 1 hit paper
7 papers, 621 citations indexed

About

L. Bouhlel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, L. Bouhlel has authored 7 papers receiving a total of 621 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in L. Bouhlel's work include Lung Cancer Treatments and Mutations (6 papers), Cancer Genomics and Diagnostics (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). L. Bouhlel is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer Genomics and Diagnostics (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). L. Bouhlel collaborates with scholars based in France. L. Bouhlel's co-authors include Charles‐Hugo Marquette, Marius Ilié, Paul Hofman, Véronique Hofman, Élodie Long-Mira, M. Poudenx, Jérôme Mouroux, Josiane Otto, Coraline Bence and Salomé Lalvée and has published in prestigious journals such as Annals of Oncology, Current Molecular Medicine and Expert Review of Anticancer Therapy.

In The Last Decade

L. Bouhlel

6 papers receiving 619 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

2015 459 citations Marius Ilié, Élodie Long-Mira et al. Annals of Oncology profile →

Peers

Countries citing papers authored by L. Bouhlel

Since Specialization

Citations

This map shows the geographic impact of L. Bouhlel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Bouhlel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Bouhlel more than expected).

Fields of papers citing papers by L. Bouhlel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Bouhlel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Bouhlel. The network helps show where L. Bouhlel may publish in the future.

Co-authorship network of co-authors of L. Bouhlel

This figure shows the co-authorship network connecting the top 25 collaborators of L. Bouhlel. A scholar is included among the top collaborators of L. Bouhlel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Bouhlel. L. Bouhlel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer 2022 ·Cancer/Radiothérapie ·(unknown), (unknown), L. Bouhlel, (unknown), Josiane Otto, A.O. Naghavi, (unknown), Antonin Lévy, (unknown), M. Poudenx, Thierry Passeron, J.‐P. Lacour, Henri Montaudié, J. Doyen	2
2	Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab 2020 ·Bulletin du Cancer ·L. Bouhlel, J. Doyen, Emmanuel Chamorey, M. Poudenx, Marius Ilié, Jocelyn Gal, J. Guigay, Jonathan Benzaquen, Charles‐Hugo Marquette, Jean‐Philippe Berthet, Jérôme Mouroux, Renaud Schiappa, B. Padovani, Paul Hofman, Josiane Otto	21
3	Allergies aux anti-cancéreux 2018 ·Revue française d'allergologie ·(unknown), L. Bouhlel, Michaël Levraut, (unknown), Sylvie Leroy	0
4	The liquid biopsy: a tool for a combined diagnostic and theranostic approach for care of a patient with late-stage lung carcinoma presenting with bilateral ocular metastases 2017 ·Expert Review of Anticancer Therapy ·L. Bouhlel, Véronique Hofman, C. Maschi, Marius Ilié, Maryline Allégra, Charles‐Hugo Marquette, Clarisse Audigier-Valette, Juliette Thariat, Paul Hofman	14
5	Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies breakdown → 2015 ·Annals of Oncology ·Marius Ilié, Élodie Long-Mira, Coraline Bence, Catherine Butori, Sandra Lassalle, L. Bouhlel, (unknown), Katia Zahaf, Salomé Lalvée, Kevin Washetine, Jérôme Mouroux, Nicolas Vénissac, M. Poudenx, Josiane Otto, Jean‐Christophe Sabourin, Charles‐Hugo Marquette, Véronique Hofman, Paul Hofman	459
6	KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives 2015 ·Current Molecular Medicine ·Nicolas Guibert, Marius Ilié, Élodie Long-Mira, Véronique Hofman, L. Bouhlel, Patrick Brest, Baharia Mograbi, Charles‐Hugo Marquette, (unknown), Julien Mazières, Paul Hofman	39
7	Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies 2014 ·Annals of Oncology ·Marius Ilié, Coraline Bence, Véronique Hofman, Élodie Long-Mira, Catherine Butori, L. Bouhlel, Salomé Lalvée, Jérôme Mouroux, M. Poudenx, Josiane Otto, Charles‐Hugo Marquette, Paul Hofman	86

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact